Zota Health Care Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹199 Cr +54.3% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
ZH

Zota Health Care Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Zota Health Care Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹143Cr
+98.6% YoY
+10.9% QoQ
Net profit
−₹30Cr
Q3 FY25: −₹19 Cr
Margin
−0.3%
+7.7 pp YoY
−5.2 pp QoQ
Price₹1,087
Market cap₹3.9K Cr

The short version

Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years. EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added.

From Zota Health Care Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years.
  • Gross margins have improved YoY from 55% to nearly 60%, driven by higher Davaindia revenue contribution.
  • Planned aggressive expansion with 800-1,000 new COCO stores annually; next year's store addition to be more evenly phased (~200-250 per quarter).
  • Footfalls at mature stores rising (80-100 daily customers for >2 years stores), with overall footfall stable despite new low-traffic stores.

2 more points from Zota Health Care Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia.
  • Majority of the funds are used for new store expansions and working capital requirements within Davaindia.
  • A smaller portion of the QIP funds is allocated to General Corporate Purposes.
  • The company has incorporated a new wholly owned subsidiary, KMHP Ventures Limited, to engage in marketing and trading of pharmaceutical products, enhancing control over sourcing, distribution, and margin optimization.
  • Additional equity has been infused in Davaindia Health Mart Limited to support COCO store expansion and working capital.

2 more points from Zota Health Care Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant points related to store expansion and order pipeline include: - For the current financial year, the company targeted opening 800 COCO stores, with 355 stores opened in the first two quarters. - In Q3, they front-loaded store additions, putting over 500 stores into the pipeline for accelerated execution. - Moving forward, store additions are expected to be evenly phased with 200-250 stores put into process each quarter.

2 more points from Zota Health Care Ltd's call on order book

Create a free account to keep reading this call

Zota Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Zota Health Care Ltd Q3 FY26 results — key figures

Zota Health Care Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue14372+98.6%129+10.9%
Operating profit (EBITDA)-0-6—6-100%
Operating margin-0.3%-8%+7.7 pp4.9%-5.2 pp
Profit before tax-26-18—-14—
Net profit (PAT)-30-19—-16—
EPS (₹)-8.73-6.78—-5.20—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹199 Cr, net loss ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Zota Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Zota Health Care Ltd Q3 FY26 results?

Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years. EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added.

What is Zota Health Care Ltd share price analysis?

Zota Health Care Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹3,918 Cr. Investors should review the full earnings analysis for detailed insights.

Is Zota Health Care Ltd planning capital expenditure?

The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia.

Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.